{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:14:32Z","timestamp":1788200072312,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T00:00:00Z","timestamp":1516924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T00:00:00Z","timestamp":1516924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Posaconazole is a triazole antifungal used to prevent invasive fungal infections (IFIs) in patients receiving chemotherapy or haemotopoietic stem cell transplantation. Due to highly variable bioavailability of the oral suspension formulation, a delayed-release tablet was developed which showed improved bioavailability. A minimal target posaconazole plasma concentration of 0.7\u2009mg\/L is recommended for prophylaxis of IFIs. However, the relationship between plasma concentration of posaconazole and its efficacy against IFIs remains unclear. We analysed trough posaconazole concentrations and response against IFIs in 50 and 104 patients with haematologic malignancies receiving prophylactic posaconazole as the tablet or suspension formulation, respectively. Mean plasma concentration of posaconazole was 1.91\u2009\u00b1\u20091.06\u2009mg\/L and 0.82\u2009\u00b1\u20090.57\u2009mg\/L in the tablet and the oral suspension group, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The percentage of patients reaching the minimal target concentration of 0.7\u2009mg\/L was 92.0% and 47.1% in the tablet and oral suspension groups, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Emergent aspergillosis occurred in 9 (8.7%) patients in the suspension group and in none of the patients taking the tablet formulation (<jats:italic>p<\/jats:italic>\u2009=\u20090.032). Our results show a relationship between plasma concentrations of posaconazole and its prophylactic efficacy in patients with haematologic malignancies. Target posaconazole concentrations are reached more efficiently with the tablet than with the suspension formulation.<\/jats:p>","DOI":"10.1038\/s41598-018-20136-3","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T15:33:24Z","timestamp":1516635204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies"],"prefix":"10.1038","volume":"8","author":[{"given":"Elisabeth","family":"Leclerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Combarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Uzunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-5189","authenticated-orcid":false,"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl","family":"Zahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,26]]},"reference":[{"key":"20136_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1586\/17512433.2015.1034689","volume":"8","author":"JN Moore","year":"2015","unstructured":"Moore, J. N., Healy, J. R. & Kraft, W. K. Pharmacologic and clinical evaluation of posaconazole. Expert Rev. Clin. Pharmacol. 8, 321\u201334 (2015).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"20136_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2125.2010.03680.x","volume":"70","author":"HP Lipp","year":"2010","unstructured":"Lipp, H. P. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br. J. Clin. Pharmacol. 70, 471\u201380 (2010).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"20136_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00228-016-2057-6","volume":"72","author":"K Vanstraelen","year":"2016","unstructured":"Vanstraelen, K. et al. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. Eur. J. Clin. Pharmacol. 72, 953\u201363 (2016).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"20136_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/AAC.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna, G., Moton, A., Ma, L., Medlock, M. M. & McLeod, J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53, 958\u201366 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR5","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1128\/AAC.00240-09","volume":"53","author":"GR Thompson 3rd","year":"2009","unstructured":"Thompson, G. R. 3rd et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother. 53, 2223\u20134 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR6","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1128\/AAC.00150-10","volume":"54","author":"WC Neubauer","year":"2010","unstructured":"Neubauer, W. C. et al. Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob. Agents Chemother. 54, 4029\u201332 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijantimicag.2010.11.021","volume":"37","author":"AM Bryant","year":"2011","unstructured":"Bryant, A. M., Slain, D., Cumpston, A. & Craig, M. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int. J. Antimicrob. Agents 37, 266\u20139 (2011).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"20136_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10096-011-1288-9","volume":"31","author":"C Eiden","year":"2012","unstructured":"Eiden, C. et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur. J.Clin. Microbiol. Infect. Dis. 31, 161\u20137 (2012).","journal-title":"Eur. J.Clin. Microbiol. Infect. Dis."},{"key":"20136_CR9","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1128\/AAC.00581-15","volume":"59","author":"A Cumpston","year":"2015","unstructured":"Cumpston, A. et al. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob. Agents Chemother. 59, 4424\u20138 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR10","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1128\/AAC.02448-13","volume":"58","author":"WK Kraft","year":"2014","unstructured":"Kraft, W. K. et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob. Agents Chemother. 58, 4020\u20135 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","volume":"10","author":"BGJ Dekkers","year":"2016","unstructured":"Dekkers, B. G. J. et al. Therapeutic Drug Monitoring of Posaconazole: an Update. Curr. Fungal Infect. Rep. 10, 51\u201361 (2016).","journal-title":"Curr. Fungal Infect. Rep."},{"key":"20136_CR12","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1128\/AAC.00496-15","volume":"59","author":"U Durani","year":"2015","unstructured":"Durani, U. et al. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension. Antimicrob. Agents Chemother. 59, 4914\u20138 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR13","doi-asserted-by":"crossref","unstructured":"Tverdek, F. P., Heo, S. T., Aitken, S. L., Granwehr, B. & Kontoyiannis, D. P. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. Antimicrob. Agents Chemother. 61 (2017).","DOI":"10.1128\/AAC.00188-17"},{"key":"20136_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/CJI.0b013e3181f4c208","volume":"33","author":"O Adotevi","year":"2010","unstructured":"Adotevi, O. et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33, 991\u20138 (2010).","journal-title":"J. Immunother."},{"key":"20136_CR15","first-page":"3460892","volume":"2017","author":"M Belling","year":"2017","unstructured":"Belling, M. et al. Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leuk. Res. Treatment 2017, 3460892 (2017).","journal-title":"Leuk. Res. Treatment"},{"key":"20136_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee, H. R. et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 69, 1162\u201376 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"20136_CR17","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1128\/AAC.00802-12","volume":"56","author":"MJ Dolton","year":"2012","unstructured":"Dolton, M. J. et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56, 5503\u201310 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR18","doi-asserted-by":"crossref","unstructured":"Cornely, O. A. et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J. Antimicrob. Chemother. 71, 718\u201326 (2016).","DOI":"10.1093\/jac\/dkv380"},{"key":"20136_CR19","doi-asserted-by":"crossref","unstructured":"Pettit, N. N. et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J. Antimicrob. Chemother. (2017).","DOI":"10.1093\/jac\/dkx122"},{"key":"20136_CR20","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1128\/AAC.04035-14","volume":"58","author":"DS Jung","year":"2014","unstructured":"Jung, D. S., Tverdek, F. P. & Kontoyiannis, D. P. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob. Agents Chemother. 58, 6993\u20135 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20136_CR21","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw, B. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813\u201321 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"20136_CR22","doi-asserted-by":"crossref","unstructured":"Decosterd, L. A. et al. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob. Agents Chemother. 54, 5303\u201315 (2010).","DOI":"10.1128\/AAC.00404-10"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20136-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:33:23Z","timestamp":1671586403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20136-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,26]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["20136"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-20136-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,26]]},"assertion":[{"value":"6 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1681"}}